Abstract Body

Background: Recent finding showed that specific HIV integrase (IN) polymorphisms at positions S119, T122 and R231 affect integration site targeting in the host genome. Moreover, mutations at position S119 have been associated with HLA selection. We thus characterized the prevalence of IN polymorphisms at these positions and their association with CD4 cell count and HIV-RNA in HIV-1 infected HAART-naïve patients.

Methods: The association between IN polymorphisms at position S119, T122 and R231 with CD4 count and HIV-RNA has been evaluated in a cohort of HAART-naïve patients with IN genotypic resistance test (GRT). In patients with at least 2 HIV-RNA/CD4 measurements before HAART start, survival analyses were used to evaluate the event of starting HAART or to reach a CD4 cell count <350 cells/µl.

Results: 625 patients, mainly HIV-1 subtype B infected (B: 71.2%; CRF_02AG: 7.2%, F: 6.6%, C: 3.7%, other subtypes: 11.3%) have been enrolled. The following IN polymorphisms were found: at position 119, P (19.2%), G (9.0%) and A/R/T (8.7%); at position 122, I (20.8%) and S/V (2.1%); at position 231, K (1.8%).
One hundred sixty-nine patients, with available follow-up before treatment start (median [IQR] time: 13.1 [5.5-24.1] months) were longitudinally analysed. Baseline CD4 count and HIV-RNA were 458 (IQR: 376-600) cells/µl and 4.6 (IQR: 4.1-5.0) log10cps/mL, respectively. At baseline, no significant associations between polymorphisms at positions 119/122/231 with CD4 count and HIV-RNA were found. The median [95% CI] time of starting HAART or to reach a CD4 count <350 cell/µl was 15.8 [12.8-18.6] months. Interestingly, patients with 119P mutation showed a shorter time to reach the end-point compared to those with G or Swt residues (9.3 [5.6-13.0] vs. 14.7 [9.4-20.0] vs. 16.8 [14.0-19.7] months, p=0.020). Cox multivariable analyses (adjusting for age, gender, subtype, baseline CD4 and HIV-RNA) confirmed that, among all polymorphisms found at positions 119/122/231, only S119P had a higher hazard to achieve the event compared to those with 119Swt (RH [95 CI%]: 2.0 [1.2-3.2], p=0.006).

Conclusions: IN position S119, beyond the observed correlations with integration site targeting and host immune response, might define patients with accelerated disease progression. Further investigations on polymorphisms at position S119 are necessary to understand our observation.